In M&A, Public Displays of Disaffection
Wall Street Journal, The | 22 minutes ago
Keen to take advantage of declining stock valuations and investors' eagerness to cash out, corporate acquirers are increasingly backing their targets into a corner by taking their unsolicited offers public.... (more)
Latest Industry NewsMore >
Study won't sway company to pursue cheaper eye drug option -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 33 minutes ago
Free Preview - WSJ.com
Barron's | 4 hours 21 minutes ago
Apixaban Fails in VTE Study
Medscape | 5 hours ago
Study outcome won't sway company on eye drug
Los Angeles Times | 5 hours 2 minutes ago
Readers ChoiceMore >
Judge: PTC must give experimental drug to teen
FDLI SmartBrief | Aug 21, 2008
FDA rule may protect firms from disclosure lawsuits
FDLI SmartBrief | Aug 22, 2008
Top FDA officials discuss REMS, outcomes studies in roundtable
FDLI SmartBrief | Aug 25, 2008
India investigates infant deaths from drug trials
FDLI SmartBrief | Aug 20, 2008
FDA to change rules on OTC cold, cough drugs for children
FDLI SmartBrief | Aug 25, 2008
FDLI NewsMore >
What do we have in common? A lot more than you think!
FDLI SmartBrief | Aug 27, 2008
Early-bird rates apply for the Nov. 18 and 19 conference, Better Understanding CMS and Its Relationship to FDA -- The Regulation of, and Payments for, Drugs and Medical Devices!
FDLI SmartBrief | Aug 27, 2008
Food and Drug Law Journal -- The ultimate food and drug law resource
FDLI SmartBrief | Aug 26, 2008
Meet advertising, promotion experts
FDLI SmartBrief | Aug 26, 2008
Register today for Import Regulation: Protecting U.S. Consumers in a Global Economy
FDLI SmartBrief | Aug 25, 2008
Latest Industry Press ReleasesMore >
AIDS Crisis in Communities of Color Prompts Demand for National Plan to Fight HIV/AIDS
PRNewswire | 1 hour 50 minutes ago
Notification of Extraordinary General Meetings and Further Changes to Board Composition
PRNewswire | 3 hours 49 minutes ago
VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
PRNewswire | 4 hours 20 minutes ago
Zimmer Holdings to Present at Thomas Weisel Partners Conference
PRNewswire | 5 hours 19 minutes ago
Neurogen Corporation Receives Notification from Nasdaq
Business Wire | 5 hours 20 minutes ago
Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis
Business Wire | 5 hours 45 minutes ago
Sign up for FDLI SmartBrief
Latest Blog Postsview more
Frequently Asked Questions (FAQs)
Drug Channels
Yellowstone Supervolcano: Only Lukewarm?
Science Blog
Army personnel show increased risk for migraine
Science Blog
Trying to satisfy too many agendas slows school reform
Science Blog
Job Listingsview more
- REGULATORY ATTORNEY
Abbott - Director, Regulatory Affairs
Johnson & Johnson - Corporate Compliance and Business Practices (Manager to Director)
Endo Pharmaceuticals - Corporate Healthcare Lawyer
Grifols Inc. - Senior Director, US Health Care Compliance
Johnson & Johnson - Food & Drug Lawyer
Buc & Beardsley - Assistant General Counsel (FDA Regulatory)
Astellas
Companies in the news
- Alpharma Inc
- Amgen Inc
- Boehringer Ingelheim
- Boston Scientific Corporation
- Celgene Corp
- GlaxoSmithKline plc
- Harvard Pilgrim Health Care
- Health Care
- Humana
- Imclone Systems Inc
- InterMune Inc
- Medtronic Inc
- Noven Pharmaceuticals
- Orthofix International
- Pfizer
Recent Poll view more polls